Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with thiotepa and carboplatin

Therapeutic Drug Monitoring

Volumn 27, Issue 6, 2005, Pages 756-765

  De Jonge, Milly E ^a   Huitema, Alwin D R ^a   Van Dam, Selma M ^a   Rodenhuis, Sjoerd ^b   Beijnen, Jos H ^a,b,c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cyclophosphamide; Metabolites; Population pharmacokinetics

Indexed keywords

2 DECHLOROETHYLCYCLOPHOSPHAMIDE; 4 HYDROXYCYCLOPHOSPHAMIDE; AMPHOTERICIN B; ANTIEMETIC AGENT; CARBOPLATIN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DRUG METABOLITE; MESNA; PHOSPHORAMIDE MUSTARD; THIOTEPA; UNCLASSIFIED DRUG; 2-DECHLOROETHYLCYCLOPHOSPHAMIDE; 4-HYDROXYCYCLOPHOSPHAMIDE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PRODRUG; TEPA;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; BLOOD SAMPLING; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; ALGORITHM; ARTICLE; BIOLOGICAL MODEL; BLOOD; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; NEOPLASM; OVARY TUMOR; TIME;

ADOLESCENT; ADULT; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BREAST NEOPLASMS; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS; PHOSPHORAMIDE MUSTARDS; PRODRUGS; THIOTEPA; TIME FACTORS; TRIETHYLENEPHOSPHORAMIDE;

EID: 33646848267     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000177224.19294.92     Document Type: Conference Paper

References (54)

1. Van Der Wall E, Beijnen JH, Rodenhuis S. High-dose chemotherapy for solid tumors. Cancer Treat Rev. 1995;21:105-132.
2. Huitema ADR, Doesburg Smits K, Mathôt RAA, et al. The clinical pharmacology of alkylating agents in high-dose chemotherapy. Anticancer Drugs. 2000;11:515-533.
3. Moore MJ. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 1991;20:194-208.
4. Boddy AV, Yule SM. Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet. 2000;38:291-304.
5. Chang TKH, Weber GF, Crespi CL, et al. Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 1993;53:5629-5637.
6. m catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997;7:211-221.
7. Ren S, Yang JS, Kalhorn TF, et al. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res. 1997;57:4229-4235.
8. Roy P, Yu LJ, Crespi CL, et al. Development of a substrate activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999;27:655-666.
9. Bohnenstengel F, Hofman U, Eichelbaum M, et al. Characterization of the cytochrome P450 involved in side-chain oxidation of cyclophosphamide in humans. Eur J Clin Pharmacol. 1996;51:297-301.
10. Yule SM, Boddy AV, Cole M, et al. Cyclophosphamide metabolism in children. Cancer Res. 1995;55:803-809.
11. Ren S, Kalhorn TF, McDonald GB, et al. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients. Clin Pharmacol Ther. 1998;64:289-301.
12. Busse D, Busch FW, Bohnenstengel F, et al. Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism. J Clin Oncol. 1997;15:1885-1896.
13. Busse D, Busch FW, Schweizer E, et al. Fractionated administration of high-dose cyclophosphamide: influence on dose-dependent changes in pharmacokinetics and metabolism. Cancer Chemother Pharmacol. 1999;43:263-268.
14. Schuler U, Waidelich P, Kolb H, et al. Pharmacokinetics and metabolism of cyclophosphamide administered after total body irradiation of bone marrow transplant recipients. Eur J Clin Pharmacol. 1991;40:521-523.
15. Chen TL, Passos-Coelho JL, Noe DA, et al. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res. 1995;55:810-816.
16. Chen TL, Kennedy MJ, Anderson LW, et al. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone-marrow transplantation. Drug Metab Dispos. 1997;25:544-551.
17. Anderson LW, Chen TL, Colvin OM, et al. Cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy. Clin Cancer Res. 1996;2:1481-1487.
18. Sladek NE, Doeden D, Powers JF, et al. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat Rep. 1984;68:1247-1254.
19. Schuler U, Ehninger G, Wagner T. Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites. Cancer Chemother Pharmacol. 1987;20:248-252.
20. Moore MJ, Hardy RW, Thiessen JJ, et al. Rapid development of enhanced clearance after high-dose cyclophosphamide. Clin Pharmacol Ther. 1988;44:622-628.
21. Nieto Y, Xu X, Cagnoni PJ, et al. Nonpredictable pharmacokinetic behaviour of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosurea. Clin Cancer Res. 1999;5:747-751.
22. Huitema ADR, Kerbush T, Tibben MM, et al. Reduction of cyclophosphamide-bioactivation by thiotepa: critical sequence-dependency in highdose chemotherapy regimens. Cancer Chemother Pharmacol. 2000;46:119-127.
23. Huitema ADR, Mathôt RAA, Tibben MM, et al. A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide. J Pharmacokinet Pharmacodyn. 2001;28:211-230.
24. De Jonge ME, Huitema ADR, Rodenhuis S, et al. Integrated population pharmacokinetic model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction. J Pharmacokinet Pharmacodyn. 2004;31:135-156.
25. Azagra P, Perez-Ruizo JJ, Alberola V, et al. Population pharmacokinetic study of high-dose cyclophosphamide in a program of high-dose chemotherapy and peripheral blood stem cell transplantation in high risk breast cancer patients (abstract). Proc Am Soc Clin Oncol. 1998;17:81.
26. Hassan M, Svensson USH, Ljungman P, et al. A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients. Br J Clin Pharmacol. 1999;48:669-677.
27. Batey MA, Wright JG, Azzabi A, et al. Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Eur J Cancer. 2002;38:1081-1089.
28. Williams ML, Wainer IW, Granvil CP, et al. Population pharmacokinetics of (R)- and (S)-cyclophosphamide and their dechloroethylated metabolites in cancer patients. Chirality. 1999;11:301-308.
29. Tasso MJ, Boddy AV, Price L, et al. Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients. Cancer Chemother Pharmacol. 1992;30:207-211.
30. Rae JM, Soukhova NV, Flockhart DA, et al. Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Dispos. 2002;30:525-530.
31. Lind MJ, McGown AT, Hadfield JA, et al. The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochem Pharmacol. 1989;38:1835-1840.
32. Borner K, Kisro J, Bruggeman SK, et al. Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo. Drug Metab Dispos. 2000;28:573-576.
33. Bruggeman SK, Kisro J, Wagner T. Ifosfamide cytotoxicity on human tumor and renal cells: a role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide. Cancer Res. 1997;57:2676-2680.
34. Goren MP, Wright RK, Pratt CB, et al. Dechloroethylation of ifosfamide and neurotoxicity. Lancet. 1986;2:1219-1220.
35. Kerbusch T, de Kraker J, Keizer HJ, et al. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet. 2001;40:41-62.
36. Huitema ADR, Reinders C, Tibben MM, et al. Sensitive gas chromatographic determination of the cyclophosphamide metabolite 2-dechloroethylcyclophosphamide in human plasma. J Chromatogr B. 2001;757:349-357.
37. Rodenhuis S, Richel DJ, Van Der Wall E, et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet. 1998;352:515-521.
38. Rodenhuis S, Westerman A, Holtkamp MJ, et al. Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. J Clin Oncol. 1996;14:1473-1483.
39. Rodenhuis S, De Wit R, De Mulder PHM, et al. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. Ann Oncol. 1999;10:1467-1473.
40. Rodenhuis S, Bontenbal M, Beex LV, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med. 2003;349:7-16.
41. Huitema ADR, Kerbusch T, Tibben MM, et al. Reduction of cyclophosphamide-bioactivation by thiotepa: critical sequence-dependency in high-dose chemotherapy regimens. Cancer Chemother Pharmacol. 2000;46:119-127.
42. Huitema ADR, Holtkamp M, Tibben MM, et al. Sampling technique from central venous catheters proves critical for pharmacokinetic studies. Ther Drug Monit. 1999;21:102-104.
43. De Jonge ME, Mathôt RAA, Van Dam SM, et al. Sorption of thiotepa to polyurethane catheter causes falsely elevated plasma levels. Ther Drug Monit. 2003;25:261-263.
44. Huitema ADR, Tibben MM, Kerbusch T, et al. Simultaneous determination of N,N′,N″-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography. J Chromatogr B Biomed Sci Appl. 1998;716:177-186.
45. Huitema ADR, Tibben MM, Kerbusch T, et al. High performance liquid chromatographic determination of the stabilized cyclophosphamide metabolite 4-hydroxycyclophosphamide in plasma and red blood cells. J Liq Chromatogr Rel Technol. 2000;23:1725-1744.
46. Huitema ADR, Tibben MM, Kerbusch T, et al. Simple and selective determination of the active cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography. J Chromatogr B. 2000;745:345-355.
47. Beal SL, Sheiner LB. User's Guides. San Francisco: NONMEM Project Group, University of California at San Francisco, 1998.
48. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481-504.
49. Jonsson EN, Karlsson MO. X-pose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51-64.
50. Yule SM, Price L, Cole M, et al. Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion. Cancer Chemother Pharmacol. 2001;47:222-228.
51. Lindley C, Hamilton G, McCune JS, et al. The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos. 2002;30:814-821.
52. Chang TKH, Yu L, Maurel P, et al. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997;57:1946-1954.
53. Gervot L, Rochat B, Gautier JC, et al. Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics. 1999;9:295-306.
54. Martin H, Sarsat JP, De Waziers I, et al. Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices. Pharm Res. 2003;20:557-568.